ClinicalTrials.gg
Active, not recruitingNCT06532656Updated Sep 29, 2026

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

A Phase 2/3 interventional study of Lenacapavir and Bictegravir/Lenacapavir (BIC/LEN) FDC in HIV-1-infection, sponsored by Gilead Sciences. Active, not recruiting at 21 sites in 5 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

Updated Sep 29, 2026Primary completion movedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Study summary

The goal of this clinical study is to learn about the safety and tolerability of bictegravir (BIC)/lenacapavir (LEN) and to learn how the study drug interacts with the body in virologically suppressed (VS) children and adolescents with human immunodeficiency virus type 1 (HIV-1) on a stable and complex antiretroviral (ARV) regimen. The study will also assess the safe loading dose of LEN and pharmacokinetics (PK) of BIC/LEN.

The primary objectives of this study are:

  • To evaluate the steady-state PK of BIC and LEN and confirm the dose of the LEN loading dose and BIC/LEN FDC in VS children and adolescents with HIV-1.
  • To evaluate the safety and tolerability of BIC/LEN through Week 24 in VS children and adolescents with HIV-1.
02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age and body weight at screening:

    • Cohort 1: ≥ 12 years to \< 18 years weighing ≥ 35 kg.
    • Cohort 2: ≥ 6 years to \< 12 years weighing ≥ 25 kg to \< 35 kg.
    • Cohort 3: ≥ 2 years to \< 6 years weighing ≥ 10 kg to \< 25 kg.
  • On a complex ARV regimen. Complex regimens are any ARV therapy that is not a single-tablet regimen taken once daily (eg, > 1 tablet or any other formulation a day).
  • Documented plasma -1 ribonucleic acid (RNA) levels must be \< 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is \< 50 copies/mL) in the last 6 months prior to screening (at least 1 measure prior to screening).
  • Plasma HIV-1 RNA levels \< 50 copies/mL at screening.
  • No documented or suspected resistance to integrase strand transfer inhibitors (mutations T66A/I/K, E92G/Q/V, G118R, F121C/Y, G140R, Y143C/H/R, S147G, Q148H/K/R, N155H/S, or R263K in the integrase gene).
  • The following laboratory parameters at screening:

    • Estimated ≥ 30 mL/min/1.73 m2 using the Bedside Schwartz formula.
    • > 0.50 cells/L (> 500 cells/mm3).
    • ≥ 85 g/L (> 8.5 g/dL).
    • ≥ 50 cells/L (≥ 50,000 cells/mm3).
    • Hepatic transaminases ( and alanine aminotransferase)

      ≤ 5 x .

    • Total ≤ 23 μmol/L (≤ 1.5 mg/dL) and direct bilirubin ≤ 7 μmol/L (≤ 0.4 mg/dL).

Key Exclusion Criteria:

  • \< 200 cells/mm\^3.
  • CD4 percentage \< 20%.
  • ≤ 1 year.
  • An opportunistic illness indicative of Stage 3 HIV diagnosed within the 30 days prior to screening.
  • Evidence of active pulmonary or extrapulmonary tuberculosis within 3 months prior to screening.
  • Acute hepatitis within 30 days prior to screening.
  • Positive virus (HCV) antibody with detectable HCV RNA (participants positive for HCV antibody will have an HCV RNA test performed).
  • Positive surface antigen (HBsAg) or positive hepatitis B virus (HBV) core antibody (antibody against hepatitis B core antigen [anti-HBc]) at screening. If a participant is negative for HBsAg and positive for anti-HBc but HBV DNA is undetectable, the participant may be enrolled.
  • A history of or current decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).Current alcohol or substance use judged by the investigator to potentially interfere with the participant's study compliance.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Participants Aged ≥ 12 to < 18 years with Weight ≥ 35 kg: BIC/LEN TOS 75/50 mg FDC

    Participants will receive a 2-day oral loading dose of LEN (600 mg) on Days 1 and 2 and daily oral BIC/LEN TOS 75/50 mg starting on Day 1 through Week 48. Following Week 48, participants will have an option to continue BIC/LEN in the extension period.

    Drug: Lenacapavir · Drug: Bictegravir/Lenacapavir (BIC/LEN) FDC

  • Experimental
    Cohort 2: Participants Aged ≥ 6 to < 12 years with Weight ≥ 25 kg to < 35 kg

    All participants will receive a 2-day oral loading dose of LEN, and daily oral BIC and LEN dose starting on Day 1 through Week 48. Dose in cohort 2 to be defined. Following Week 48, participants will have an option to continue BIC/LEN in the extension period.

    Drug: Lenacapavir · Drug: Bictegravir/Lenacapavir

  • Experimental
    Cohort 3: Participants Aged ≥ 2 to < 6 years with Weight ≥ 10 kg to < 25 kg

    All participants will receive a 2-day oral loading dose of LEN, and daily oral BIC and LEN dose starting on Day 1 through Week 48. Dose in cohort 3 to be defined. Following Week 48, participants will have an option to continue BIC/LEN in the extension period.

    Drug: Lenacapavir · Drug: Bictegravir/Lenacapavir

Interventions

  • Tablets administered orally without regard to food

    Also known as: GS-6207

  • DrugBictegravir/Lenacapavir (BIC/LEN) FDC

    Drug pages: Bictegravir · Lenacapavir

    Tablets administered orally without regard to food

    Also known as: Bixlenvo™

  • DrugBictegravir/Lenacapavir

    Drug pages: Bictegravir · Lenacapavir

    Tablets administered orally without regard to food

06

What researchers measure

Primary outcomes

  1. PK Parameter: Cmax of BIC and LEN at Steady State

    Cmax is defined as the maximum observed concentration of drug at steady state.

    Time frame: Day 1 up to Week 24, as appropriate

  2. PK Parameter: AUCtau of BIC and LEN at Steady State

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady state.

    Time frame: Day 1 up to Week 24, as appropriate

  3. PK Parameter: Ctrough of BIC and LEN at Steady State

    Ctrough is defined as the observed drug concentration at the end of the dosing interval at steady state.

    Time frame: Day 1 up to Week 24, as appropriate

  4. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24

    Time frame: First dose date up to Week 24

  5. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 24

    Time frame: First dose date up to Week 24

Secondary outcomes

  1. PK Parameter: AUClast for BIC and LEN at Steady State

    AUClast is defined as the area under the concentration versus time curve from time zero to the last quantifiable concentration at steady state.

    Time frame: Day 1 up to Week 48, as appropriate

  2. PK Parameter: Tmax for BIC and LEN at Steady State

    Tmax is defined as the time (observed time point) of Cmax at steady state.

    Time frame: Day 1 up to Week 48, as appropriate

  3. PK Parameter: Tlast for BIC and LEN at Steady State

    Tlast is defined as the time (observed time point) of Clast at steady state. Clast is defined as the last measurable concentration (above the quantification limit).

    Time frame: Day 1 up to Week 48, as appropriate

  4. PK Parameter: T1/2 for BIC and LEN at Steady State

    T1/2 is defined as the terminal elimination half-life at steady state.

    Time frame: Day 1 up to Week 48, as appropriate

  5. PK Parameter: CL for BIC and LEN at Steady State

    Clearance (CL) is the volume of plasma cleared of drug over a specified time period, at a steady state.

    Time frame: Day 1 up to Week 48, as appropriate

  6. PK Parameter: Vz for BIC and LEN at Steady State

    Volume of distribution (Vz) is defined as the extent to in which the drug is distributed in the body tissue, rather than the plasma, to produce the desired effects at a steady state.

    Time frame: Day 1 up to Week 48, as appropriate

  7. PK Parameter: λz for BIC and LEN at Steady State

    λz is defined as the terminal elimination rate constant, which determines the rate at which the drug will be eliminated from the body after it is absorbed and distributed at a steady state.

    Time frame: Day 1 up to Week 48, as appropriate

  8. Percentage of Participants Experiencing TEAEs Through Week 48

    Time frame: First dose date up to Week 48

  9. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 48

    Time frame: First does date up to Week 48

  10. Proportion of Participants With Plasma HIV-1 RNA < 50 copies/mL and ≥ 50 copies/mL at Week 24 Based on the United States (US) Food and Drug Administration (FDA)-Defined Snapshot Algorithm

    Time frame: Week 24

  11. Proportion of Participants With Plasma HIV-1 RNA < 50 copies/mL and ≥ 50 copies/mL at Week 48 Based on the United States FDA-Defined Snapshot Algorithm

    Time frame: Week 48

  12. Change from Baseline in Clusters of Differentiation 4 (CD4) Cell Counts at Week 24

    Time frame: Baseline, Week 24

  13. Change from Baseline in CD4 Percentage at Week 24

    Time frame: Baseline, Week 24

  14. Change from Baseline in CD4 Cell Counts at Week 48

    Time frame: Baseline, Week 48

  15. Change from Baseline in CD4 Percentage at Week 48

    Time frame: Baseline, Week 48

  16. Acceptability and Palatability Summary of LEN Oral Loading Dose at Day 1 Assessed by Questionnaire

    Palatability and acceptability assessed by a numeric response between numbers 1-5. Higher scores indicate better palatability and acceptability.

    Time frame: Day 1

  17. Acceptability and Palatability Summary of LEN Oral Loading Dose at Day 2 Assessed by Questionnaire

    Palatability and acceptability assessed by a numeric response between numbers 1-5. Higher scores indicate better palatability and acceptability.

    Time frame: Day 2

  18. Acceptability and Palatability Summary of Oral BIC/LEN Fixed Dose Combination (FDC) at Day 1 Assessed by Questionnaire

    Palatability and acceptability assessed by a numeric response between numbers 1-5. Higher scores indicate better palatability and acceptability.

    Time frame: Day 1

  19. Acceptability and Palatability Summary of Oral BIC/LEN FDC at Week 4 Assessed by Questionnaire

    Palatability and acceptability assessed by a numeric response between numbers 1-5. Higher scores indicate better palatability and acceptability.

    Time frame: Week 4

  20. Acceptability and Palatability Summary of Oral BIC/LEN FDC at Week 24 Assessed by Questionnaire

    Palatability and acceptability assessed by a numeric response between numbers 1-5. Higher scores indicate better palatability and acceptability.

    Time frame: Week 24

  21. Acceptability and Palatability Summary of Oral BIC/LEN FDC at Week 48 Assessed by Questionnaire

    Palatability and acceptability assessed by a numeric response between numbers 1-5. Higher scores indicate better palatability and acceptability.

    Time frame: Week 48

07

Study locations

21 sites
  • Children's National Hospital
    Washington D.C., District of Columbia 20010, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Grady Ponce de Leon Center
    Atlanta, Georgia 30308, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60614, United States
  • Helios Salud S.A
    Buenos Aires, C1141ACG,, Argentina
  • ASST FBF Sacco Ospedale Sacco
    Milan, 20157, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesu, UOS Infezioni Complesse e Perinatali
    Roma, 00165, Italy
  • FAMCRU Ukwanda School for Rural Health
    Cape Town, 7505, South Africa
  • Be Part Yoluntu
    Cape Town, 7646, South Africa
  • Durban International Clinical Research Site, Enhancing Care Foundation
    Durban, 3629, South Africa
  • Monti Clinical Research Centre
    East London, 5219, South Africa
  • Perinatal HIV Research Unit
    Johannesburg, 1862, South Africa
  • Wits RHI Shandukani Research Centre CRS
    Johannesburg, 2038, South Africa
  • Nkanyezi VIDA Research Unit
    Johannesburg, 2112, South Africa
  • Khomanani Health Research and Wellness Centre
    Ka-Majosi, 944, South Africa
  • Clinical Research Institute of South Africa (CRISA)
    KwaDukuza, 4449, South Africa
  • The Aurum Institute: Pretoria Clinical Research Centre
    Pretoria, 0087, South Africa
  • Setshaba Research Centre
    Soshanguve, 0152, South Africa
  • Hospital General Universitario Gregorio Marano
    Madrid, 28007, Spain
  • Hospital Universitario 12 De Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jul 2030, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 1, 2024
StartActual
Nov 20, 2024
Primary completionEst.
Jul 2030
CompletionEst.
Dec 2030
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Changed, then back to Jul 2030
moved 2 times, Sep 28, 2026 – Sep 29, 2026
Interventions
Changed BIC/LEN FDC→Bictegravir/Lenacapavir (BIC/LEN) FDC. Added Drug: Bictegravir/Lenacapavir. Arm changed Cohort 1: Participants Aged ≥ 12 to < 18 years with Weight ≥ 35 kg: BIC/LEN 75/50 mg FDC→Cohort 1: Participants Aged ≥ 12 to < 18 years with Weight ≥ 35 kg: BIC/LEN TOS 75/50 mg FDC
Sep 28, 2026
Show all 2 updates
  1. Sep 29, 2026
    Primary completion Nov 2026→Jul 2030
  2. Sep 28, 2026
    Primary completion Jul 2030→Nov 2026
    Interventions Changed BIC/LEN FDC→Bictegravir/Lenacapavir (BIC/LEN) FDC. Added Drug: Bictegravir/Lenacapavir. Arm changed Cohort 1: Participants Aged ≥ 12 to < 18 years with Weight ≥ 35 kg: BIC/LEN 75/50 mg FDC→Cohort 1: Participants Aged ≥ 12 to < 18 years with Weight ≥ 35 kg: BIC/LEN TOS 75/50 mg FDC
    + 5 other changes: index terms, identifiers, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06532656
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Nov 20, 2024
Primary completion
Jul 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Sep 29, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Lenacapavir

Start the discussion